Clinical Trial Update: A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating oral lorlatinib in patients with relapsed ALK-positive anaplastic large cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma Alk-positive

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: University of Milano Bicocca | Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Status: UNKNOWN